B3GAT1 and acute lymphoblastic leukemia: Patients with standard-risk hematology malignancy (AML and acute lymphoblastic leukemia, ALL in first complete remission, malignant lymphoma in complete remission, chronic myeloid leukemia, CLL in chronic phase and any status of a myelodysplastic syndrome) undergoing HSCT with HNK1 haplotype donor have lower transplantation-related mortality and better overall survival (difference in 5-year overall survival of 73% vs. 49%, p=0.01) (18).